Over 10,000 Lawsuits In Novo Nordisk’s Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest.
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.
AbbVie’s Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance patient access and incentivize development.
Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
Companies from food and beverage to fitness are adapting to the increased demand for these drugs, hoping to capitalize on shifting consumer habits
FDA Approves Geron’s First Commercial Drug, Competes With Bristol Myers Squibb’s Blood Cancer Drug
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market potential of $1.2 billion.
SeaStar Medical Announces The Publication Of A Peer-Reviewed Article In ‘Nature Scientific Reports’ Describes The Mechanism Of Action Of The Co’s Selective Cytopheretic Device In The Immunomodulation Of Excessive Inflammation
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the publication of a
Venus Concept Stock Soars 127% Premarket After Regaining Nasdaq Compliance
As part of the compliance, Venus Concept will be under a mandatory panel monitor until June 4, 2025.
This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials
Elevated liver enzyme levels were noted, although most adverse events were mild to moderate, with no severe reactions reported.
Tevogen Bio Confirms Ongoing Efficacy Of TVGN 489 Against Dominant FLiRT Strains Of SARS-CoV-2
Tevogen Bio Holdings Inc. ("Tevogen" or "Tevogen Bio") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology,
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month.